5th Annual Live Medical Crossfire®: Hematologic Malignancies

Physicians’ Education Resource® (PER®) presents the 5th Annual Live Medical Crossfire®: Hematologic Malignancies—a 1-day Medical Crossfire® designed to interactively explore the most controversial clinical issues in the field of hematologic malignancies through live,...
Haematology
Physicians’ Education Resource® (PER®) presents the 5th Annual Live Medical Crossfire®: Hematologic Malignancies—a 1-day Medical Crossfire® designed to interactively explore the most controversial clinical issues in the field of hematologic malignancies through live, interactive panel discussions with renowned experts. This meeting will contrast viewpoints of key opinion leaders across the country and world regarding emerging clinical data and current standards of practice across liquid tumors. Through this valuable discussion, healthcare professionals participating in this conference can better treat a broad range of patients with hematologic malignancies, understand current controversies, and more confidently personalize clinical decisions. At the start of each Medical Crossfire® segment, renowned experts across the field of liquid tumors—from leukemias and lymphomas to myeloma—present a brief evidence-based assessment of current standards of practice and the most important clinical trials to set the stage for each expert crossfire session. Sessions conclude with a crossfire from the live audience. This innovative format provides the most practical and engaging educational forum available today in the field of hematologic malignancies. ,This live Medical Crossfire®: Hematologic Malignancies offers oncologists who are involved in the care of patients with hematologic malignancies the opportunity to interact with leading faculty, build their base of clinical knowledge, maintain awareness of controversies in the field, and apply the best practices for the care of their patients to optimize outcomes for patients.  ,Learning Objectives Upon completion of this activity, participants will be able to: ,• Analyze testing strategies that may inform clinical decision making in the management of hematologic malignancies • Apply clinical trial results to multiple lines of care in the management of hematologic malignancies • Implement optimal strategies to treat hematologic malignancies • Assess disparities in care for patients with hematologic malignancies • Develop strategies to proactively prevent, minimize, and manage treatment-related toxicities in patients with leukemia, lymphoma, or multiple myeloma • Discuss key emerging data sets regarding the management of patients with hematologic malignancies
support@emedevents.com
1(800) 828-2059
New York City, New York